182 related articles for article (PubMed ID: 19522047)
21. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
Kips JC; O'Connor BJ; Langley SJ; Woodcock A; Kerstjens HA; Postma DS; Danzig M; Cuss F; Pauwels RA
Am J Respir Crit Care Med; 2003 Jun; 167(12):1655-9. PubMed ID: 12649124
[TBL] [Abstract][Full Text] [Related]
22. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
Kay AB; Klion AD
Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
[TBL] [Abstract][Full Text] [Related]
23. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
24. [CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma].
Platzer S; Fehr T; Latshang T
Praxis (Bern 1994); 2018; 107(21):1129-1135. PubMed ID: 30326819
[TBL] [Abstract][Full Text] [Related]
25. Deal watch: Anti-IL-5 antibody attracts Cephalon to agree option for Ception acquisition.
Nat Rev Drug Discov; 2009 Mar; 8(3):185. PubMed ID: 19247299
[No Abstract] [Full Text] [Related]
26. Effective treatment with mepolizumab in a patient with refractory Wells syndrome.
Terhorst-Molawi D; Altrichter S; Röwert J; Magerl M; Zuberbier T; Maurer M; Bergmann KC; Metz M
J Dtsch Dermatol Ges; 2020 Jul; 18(7):737-739. PubMed ID: 32713149
[No Abstract] [Full Text] [Related]
27. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.
Shrimanker R; Pavord ID
BioDrugs; 2017 Apr; 31(2):93-103. PubMed ID: 28364396
[TBL] [Abstract][Full Text] [Related]
29. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
30. Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
Berair R; Pavord ID
Curr Allergy Asthma Rep; 2013 Oct; 13(5):469-76. PubMed ID: 23904099
[TBL] [Abstract][Full Text] [Related]
31. Eosinophils in asthma and airway hyperresponsiveness.
Brightling CE; Pavord ID
Am J Respir Crit Care Med; 2004 Jan; 169(1):131-2; author reply 132-3. PubMed ID: 14695110
[No Abstract] [Full Text] [Related]
32. Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis.
Conus S; Straumann A; Bettler E; Simon HU
J Allergy Clin Immunol; 2010 Jul; 126(1):175-7. PubMed ID: 20542323
[No Abstract] [Full Text] [Related]
33. New aspects in the treatment of asthma: targeted therapy.
Wang ZL
Chin Med J (Engl); 2008 Apr; 121(7):640-8. PubMed ID: 18466686
[No Abstract] [Full Text] [Related]
34. The trials and tribulations of anti-IL-5 em leader.
Hansel TT; Sterk PJ; Holgate ST; Barnes PJ
J Allergy Clin Immunol; 2002 Mar; 109(3):575-6. PubMed ID: 11898011
[No Abstract] [Full Text] [Related]
35. Association of antieosinophil therapy with decreased body mass index in patients with severe asthma: A preliminary retrospective analysis.
Kuruvilla M; Patrawala M; Levy JM; Shih J; Lee FE
Ann Allergy Asthma Immunol; 2019 Jun; 122(6):649-650. PubMed ID: 30953786
[No Abstract] [Full Text] [Related]
36. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome.
Rosenwasser LJ; Rothenberg ME
J Allergy Clin Immunol; 2010 Jun; 125(6):1245-6. PubMed ID: 20513522
[No Abstract] [Full Text] [Related]
37. Asthma Yardstick Update: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma.
Oppenheimer JJ; Borish L
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):660-661. PubMed ID: 30172715
[No Abstract] [Full Text] [Related]
38. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
39. Combination biologic therapy for severe persistent asthma.
Ortega G; Tongchinsub P; Carr T
Ann Allergy Asthma Immunol; 2019 Sep; 123(3):309-311. PubMed ID: 31251970
[No Abstract] [Full Text] [Related]
40. Eosinophils, beyond IL-5.
Esnault S; Johansson MW; Mathur SK
Cells; 2021 Oct; 10(10):. PubMed ID: 34685594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
